文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

炎症及其致病因素在原发性肝癌中的多功能作用:文献综述

Multifunctional roles of inflammation and its causative factors in primary liver cancer: A literature review.

作者信息

Chen Hong-Jin, Huang Ting-Xiong, Jiang Yu-Xi, Chen Xiong, Wang Ai-Fang

机构信息

Department of Pharmacology, School of Basic Medical Sciences, Translational Medicine Research Center, Guizhou Medical University, Guiyang 550025, Guizhou Province, China.

School of Clinical Medical, Translational Medicine Research Center, Guizhou Medical University, Guiyang 550025, Guizhou Province, China.

出版信息

World J Hepatol. 2023 Dec 27;15(12):1258-1271. doi: 10.4254/wjh.v15.i12.1258.


DOI:10.4254/wjh.v15.i12.1258
PMID:38223416
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10784815/
Abstract

Primary liver cancer is a severe and complex disease, leading to 800000 global deaths annually. Emerging evidence suggests that inflammation is one of the critical factors in the development of hepatocellular carcinoma (HCC). Patients with viral hepatitis, alcoholic hepatitis, and steatohepatitis symptoms are at higher risk of developing HCC. However, not all inflammatory factors have a pathogenic function in HCC development. The current study describes the process and mechanism of hepatitis development and its progression to HCC, particularly focusing on viral hepatitis, alcoholic hepatitis, and steatohepatitis. Furthermore, the roles of some essential inflammatory cytokines in HCC progression are described in addition to a summary of future research directions.

摘要

原发性肝癌是一种严重且复杂的疾病,每年在全球导致80万人死亡。新出现的证据表明,炎症是肝细胞癌(HCC)发生发展的关键因素之一。患有病毒性肝炎、酒精性肝炎和脂肪性肝炎症状的患者患HCC的风险更高。然而,并非所有炎症因子在HCC发生发展中都具有致病作用。本研究描述了肝炎发生发展及其进展为HCC的过程和机制,特别关注病毒性肝炎、酒精性肝炎和脂肪性肝炎。此外,除了总结未来的研究方向外,还描述了一些重要炎症细胞因子在HCC进展中的作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c9d/10784815/88b540f2bb5d/WJH-15-1258-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c9d/10784815/88b540f2bb5d/WJH-15-1258-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c9d/10784815/88b540f2bb5d/WJH-15-1258-g001.jpg

相似文献

[1]
Multifunctional roles of inflammation and its causative factors in primary liver cancer: A literature review.

World J Hepatol. 2023-12-27

[2]
Molecular pathogenesis: Connections between viral hepatitis-induced and non-alcoholic steatohepatitis-induced hepatocellular carcinoma.

Front Immunol. 2022

[3]
Nonalcoholic fatty liver disease and hepatocellular carcinoma.

Metabolism. 2016-8

[4]
Etiology of Hepatocellular Carcinoma: Special Focus on Fatty Liver Disease.

Front Oncol. 2020-11-30

[5]
Case report: Unusual development of hepatocellular carcinoma during immunosuppressive treatments against rheumatoid arthritis overlapping Sjögren's syndrome; cirrhotic steatohepatitis with liver inflammation and fibrosis lurks in autoimmune disorders.

Front Immunol. 2023

[6]
Differentiation of clinical patterns and survival outcomes of hepatocellular carcinoma on hepatitis B and nonalcoholic fatty liver disease.

J Chin Med Assoc. 2021-6-1

[7]
Hereditary hemochromatosis: Temporal trends, sociodemographic characteristics, and independent risk factor of hepatocellular cancer - nationwide population-based study.

World J Hepatol. 2022-9-27

[8]
Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma.

World J Gastroenterol. 2023-1-14

[9]
Emerging metabolic risk factors in hepatocellular carcinoma and their influence on the liver microenvironment.

Biochim Biophys Acta Mol Basis Dis. 2017-11-29

[10]
Hyperlipidemia and Nonalcoholic Steatohepatitis Predispose to Hepatocellular Carcinoma Development Without Cirrhosis.

J Clin Gastroenterol. 2019-4

引用本文的文献

[1]
Characteristics and outcomes of primary and secondary resistance to immune checkpoint inhibitors in hepatocellular carcinoma.

Cancer Immunol Immunother. 2025-6-7

本文引用的文献

[1]
Targeting N6-methyladenosine reader YTHDF1 with siRNA boosts antitumor immunity in NASH-HCC by inhibiting EZH2-IL-6 axis.

J Hepatol. 2023-11

[2]
Dicer Suppresses Hepatocellular Carcinoma via Interleukin-8 Pathway.

Clin Med Insights Oncol. 2023-4-7

[3]
Blocking the CXCL1-CXCR2 axis enhances the effects of doxorubicin in HCC by remodelling the tumour microenvironment via the NF-κB/IL-1β/CXCL1 signalling pathway.

Cell Death Discov. 2023-4-10

[4]
Curcumin-Mediated Resistance to Lenvatinib via EGFR Signaling Pathway in Hepatocellular Carcinoma.

Cells. 2023-2-14

[5]
Aspirin triggers ferroptosis in hepatocellular carcinoma cells through restricting NF-κB p65-activated SLC7A11 transcription.

Acta Pharmacol Sin. 2023-8

[6]
Efficacy of dexamethasone and N-acetylcysteine combination in preventing post-embolization syndrome after transarterial chemoembolization in hepatocellular carcinoma.

World J Gastroenterol. 2023-2-7

[7]
NLRP3 inflammasome activation By 17β-estradiol is a potential therapeutic target in hepatocellular carcinoma treatment.

Med Oncol. 2023-2-10

[8]
Association of Common Polymorphisms in the Interleukin-1 Beta Gene with Hepatocellular Carcinoma in Caucasian Patients with Chronic Hepatitis B.

Pathogens. 2022-12-29

[9]
A Critical Role of the IL-22-IL-22 Binding Protein Axis in Hepatocellular Carcinoma.

Cancers (Basel). 2022-12-7

[10]
Sorafenib inhibits doxorubicin-induced PD-L1 upregulation to improve immunosuppressive microenvironment in Osteosarcoma.

J Cancer Res Clin Oncol. 2023-7

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索